Back to results
US 2009/0275635 A1Published application
Screening method
AssigneeMedical Research Council
InventorsMariann Bienz, Felix Randow
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMedical Research Council
InventorsMariann Bienz, Felix Randow
Estimating the term…
The invention provides a method of modulating Wnt signalling comprising modulating Trabid activity. Preferably modulating Trabid activity comprises inhibiting; Trabid activity. The invention also provides a method of reducing TCF transcription, said method comprising reducing Trabid activity. A method for identifying a-modulator of Trabid said method comprising; providing a Trabid substrate comprising a detectable moiety coupled to a tag moiety by ubiquitin; immobilising first and second portions of said substrate; adding a candidate modulator to the first said portion; contacting first and second portions with Trabid; incubating to allow Trabid action, assaying cleavage of ubiquitin by separation of tag from detectable moiety, wherein separation of an amount of detectable moiety from said first portion which is different from the amount of detectable moiety separated from said second portion identifies said candidate as a modulator of Trabid. The invention provides uses of Trabid and of Trabid inhibitors as-medicaments.
(canceled)
(canceled)
A method of reducing TCF transcription, said method comprising contacting a cell with an inhibitor of Trabid activity.
(canceled)
A method of treating familial adenomatous polyposis in a subject comprising administering a modulator of Trabid signalling to said subject.
A method of treating colorectal cancer in a subject comprising administering a modulator of Trabid signalling to said subject.
(canceled)
The method according to claim 53 wherein the deubiquitylation comprises cleavage of K63 ubiquitin.
The method according to claim 53 wherein Trabid comprises at least the C-terminal ovarian tumour (OTU) domain.
The method according to claim 53 wherein Trabid comprises the N-terminal NZF finger motifs.
The method according to claim 53 wherein Trabid comprises full length human Trabid polypeptide.
16-26. (canceled)
A method for identifying a modulator of Trabid said method comprising
28-36. (canceled)
A method of modulating the armadillo repeat domain (ARD) of APC, said method comprising contacting said APC with Trabid.
(canceled)
Trabid or a fragment thereof wherein said Trabid comprises a C443 mutation.
40-51. (canceled)
A method for the deubiquitylation of a polypeptide, the method comprising contacting a ubiquitylated polypeptide with a Trabid polypeptide, wherein said ubiquitylated polypeptide is deubiquitylated by said Trabid polypeptide.
A pharmaceutical composition comprising a Trabid inhibitor and a pharmaceutically acceptable carrier.
An inhibitor of Trabid, the inhibitor comprising an siRNA to Trabid or Trabid C443S.
A method of precipitating a ubiquitylated polypeptide, the method comprising contacting said ubiquitylated polypeptide with a Trabid polypeptide.
Dependencies are inferred from the claim text.